| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 75 | 2021 | 402 | 8.140 |
Why?
|
| Heart Conduction System | 131 | 2019 | 270 | 7.180 |
Why?
|
| Bundle of His | 42 | 2019 | 55 | 4.950 |
Why?
|
| Catheter Ablation | 34 | 2021 | 223 | 4.740 |
Why?
|
| Electrocardiography | 117 | 2020 | 394 | 4.230 |
Why?
|
| Cardiac Pacing, Artificial | 47 | 2019 | 146 | 3.430 |
Why?
|
| Arrhythmias, Cardiac | 50 | 2019 | 163 | 3.270 |
Why?
|
| Heart Atria | 46 | 2017 | 176 | 3.190 |
Why?
|
| Autonomic Nervous System | 22 | 2020 | 113 | 2.950 |
Why?
|
| Dogs | 185 | 2017 | 510 | 2.610 |
Why?
|
| Ganglia, Autonomic | 18 | 2016 | 55 | 2.470 |
Why?
|
| Atrioventricular Node | 32 | 2012 | 69 | 2.420 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 30 | 2019 | 96 | 2.340 |
Why?
|
| Bundle-Branch Block | 19 | 2018 | 29 | 2.220 |
Why?
|
| Heart Rate | 63 | 2017 | 380 | 2.100 |
Why?
|
| Anti-Arrhythmia Agents | 38 | 2020 | 117 | 1.920 |
Why?
|
| Pulmonary Veins | 24 | 2016 | 108 | 1.860 |
Why?
|
| Vagus Nerve | 26 | 2020 | 106 | 1.830 |
Why?
|
| Heart | 40 | 2020 | 224 | 1.790 |
Why?
|
| Vagus Nerve Stimulation | 15 | 2020 | 76 | 1.690 |
Why?
|
| Sympathectomy | 6 | 2021 | 16 | 1.630 |
Why?
|
| Animals | 224 | 2020 | 10583 | 1.600 |
Why?
|
| Myocardial Infarction | 49 | 2017 | 351 | 1.230 |
Why?
|
| Pericardium | 10 | 2014 | 47 | 1.210 |
Why?
|
| Ligaments | 5 | 2021 | 22 | 1.200 |
Why?
|
| Renal Artery | 4 | 2020 | 15 | 1.160 |
Why?
|
| Action Potentials | 44 | 2012 | 196 | 1.130 |
Why?
|
| Electric Stimulation | 48 | 2015 | 255 | 1.070 |
Why?
|
| Electrophysiology | 41 | 2018 | 150 | 1.070 |
Why?
|
| Heart Ventricles | 28 | 2018 | 139 | 1.010 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 7 | 2017 | 29 | 1.000 |
Why?
|
| Disease Models, Animal | 37 | 2017 | 1494 | 0.980 |
Why?
|
| Sympathetic Nervous System | 6 | 2021 | 68 | 0.960 |
Why?
|
| Autonomic Pathways | 5 | 2017 | 16 | 0.950 |
Why?
|
| Tachycardia, Ventricular | 14 | 2017 | 60 | 0.850 |
Why?
|
| Body Surface Potential Mapping | 5 | 2012 | 24 | 0.830 |
Why?
|
| Humans | 85 | 2021 | 28585 | 0.800 |
Why?
|
| Cardiac Electrophysiology | 2 | 2019 | 2 | 0.730 |
Why?
|
| Heart Failure | 6 | 2019 | 250 | 0.720 |
Why?
|
| Models, Cardiovascular | 4 | 2017 | 47 | 0.690 |
Why?
|
| Atrial Function | 13 | 2011 | 22 | 0.690 |
Why?
|
| Male | 67 | 2020 | 13772 | 0.680 |
Why?
|
| Atropine | 12 | 2017 | 47 | 0.680 |
Why?
|
| Cardiac Catheterization | 20 | 2019 | 114 | 0.670 |
Why?
|
| Coronary Disease | 20 | 2003 | 120 | 0.640 |
Why?
|
| Heart Block | 31 | 2017 | 43 | 0.630 |
Why?
|
| Ciliophora | 1 | 2019 | 1 | 0.620 |
Why?
|
| Muscarinic Antagonists | 4 | 2017 | 14 | 0.610 |
Why?
|
| Clinical Medicine | 1 | 2019 | 4 | 0.610 |
Why?
|
| Cell Death | 1 | 2019 | 119 | 0.600 |
Why?
|
| Nerve Net | 4 | 2014 | 111 | 0.590 |
Why?
|
| Atrioventricular Block | 2 | 2016 | 8 | 0.590 |
Why?
|
| Pulmonary Artery | 6 | 2015 | 69 | 0.570 |
Why?
|
| Treatment Outcome | 15 | 2020 | 2402 | 0.570 |
Why?
|
| Acetylcholine | 10 | 2017 | 73 | 0.570 |
Why?
|
| Ganglia, Parasympathetic | 3 | 2014 | 10 | 0.570 |
Why?
|
| Stem Cells | 1 | 2019 | 122 | 0.570 |
Why?
|
| Cardiology | 1 | 2018 | 48 | 0.560 |
Why?
|
| Career Choice | 1 | 2018 | 53 | 0.550 |
Why?
|
| Rabbits | 20 | 2015 | 277 | 0.550 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 18 | 0.540 |
Why?
|
| Kidney | 3 | 2015 | 286 | 0.540 |
Why?
|
| Tachycardia | 29 | 2015 | 72 | 0.540 |
Why?
|
| Hypertension | 3 | 2018 | 309 | 0.530 |
Why?
|
| Ganglia, Sympathetic | 2 | 2014 | 8 | 0.530 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2011 | 66 | 0.520 |
Why?
|
| Skin | 1 | 2017 | 151 | 0.490 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 16 | 2007 | 52 | 0.490 |
Why?
|
| Denervation | 1 | 2016 | 10 | 0.490 |
Why?
|
| Atrial Appendage | 6 | 2017 | 32 | 0.480 |
Why?
|
| History, 20th Century | 4 | 2021 | 84 | 0.470 |
Why?
|
| Ganglion Cysts | 2 | 2012 | 8 | 0.460 |
Why?
|
| Autoantibodies | 6 | 2015 | 479 | 0.460 |
Why?
|
| Receptors, Adrenergic, beta-1 | 4 | 2015 | 22 | 0.450 |
Why?
|
| Autonomic Denervation | 5 | 2020 | 19 | 0.430 |
Why?
|
| Epinephrine | 5 | 2017 | 37 | 0.430 |
Why?
|
| Propranolol | 6 | 2011 | 39 | 0.430 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2011 | 58 | 0.410 |
Why?
|
| Female | 39 | 2020 | 15472 | 0.410 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 55 | 0.410 |
Why?
|
| Electric Stimulation Therapy | 6 | 2012 | 57 | 0.410 |
Why?
|
| Models, Animal | 8 | 2014 | 130 | 0.390 |
Why?
|
| Parasympatholytics | 3 | 2011 | 13 | 0.390 |
Why?
|
| Purkinje Fibers | 24 | 2000 | 37 | 0.390 |
Why?
|
| Coronary Vessels | 22 | 2013 | 153 | 0.380 |
Why?
|
| Electromagnetic Fields | 3 | 2014 | 14 | 0.380 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 3 | 2020 | 25 | 0.370 |
Why?
|
| Models, Biological | 3 | 2014 | 468 | 0.370 |
Why?
|
| Sympatholytics | 1 | 2011 | 2 | 0.370 |
Why?
|
| Lidocaine | 16 | 2017 | 27 | 0.370 |
Why?
|
| Parasympathetic Nervous System | 7 | 2003 | 17 | 0.360 |
Why?
|
| Algorithms | 2 | 2011 | 430 | 0.350 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 253 | 0.350 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2020 | 43 | 0.340 |
Why?
|
| Myocardial Ischemia | 4 | 2014 | 73 | 0.330 |
Why?
|
| Time Factors | 28 | 2018 | 1600 | 0.320 |
Why?
|
| Vena Cava, Superior | 8 | 2013 | 27 | 0.320 |
Why?
|
| History, 21st Century | 2 | 2021 | 49 | 0.310 |
Why?
|
| Tachycardia, Sinus | 2 | 2008 | 8 | 0.310 |
Why?
|
| Tachycardia, Supraventricular | 4 | 2014 | 24 | 0.300 |
Why?
|
| Sinoatrial Node | 8 | 2008 | 16 | 0.300 |
Why?
|
| Imidazoles | 8 | 2007 | 63 | 0.300 |
Why?
|
| Electric Countershock | 5 | 2020 | 29 | 0.300 |
Why?
|
| Stellate Ganglion | 5 | 2014 | 21 | 0.290 |
Why?
|
| Vagotomy | 3 | 2009 | 21 | 0.280 |
Why?
|
| Electrodes, Implanted | 7 | 2010 | 40 | 0.260 |
Why?
|
| Blood Pressure | 13 | 2015 | 355 | 0.260 |
Why?
|
| Bridged Bicyclo Compounds | 11 | 1995 | 21 | 0.260 |
Why?
|
| Refractory Period, Electrophysiological | 8 | 2016 | 21 | 0.250 |
Why?
|
| In Vitro Techniques | 17 | 2012 | 242 | 0.250 |
Why?
|
| Cardiac Complexes, Premature | 12 | 2017 | 12 | 0.230 |
Why?
|
| Receptor, Muscarinic M2 | 3 | 2017 | 15 | 0.220 |
Why?
|
| Adipose Tissue | 1 | 2006 | 186 | 0.220 |
Why?
|
| Death, Sudden | 4 | 1990 | 15 | 0.220 |
Why?
|
| Ventricular Premature Complexes | 3 | 2017 | 5 | 0.210 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2014 | 23 | 0.210 |
Why?
|
| Extracellular Space | 3 | 2002 | 26 | 0.200 |
Why?
|
| Microelectrodes | 6 | 2017 | 19 | 0.200 |
Why?
|
| Ventricular Function, Left | 4 | 2018 | 112 | 0.190 |
Why?
|
| Myocardium | 14 | 2009 | 194 | 0.180 |
Why?
|
| History, 19th Century | 1 | 2021 | 36 | 0.180 |
Why?
|
| Electrophysiological Phenomena | 3 | 2017 | 16 | 0.170 |
Why?
|
| Coronary Circulation | 6 | 1993 | 30 | 0.170 |
Why?
|
| United States | 3 | 2018 | 2201 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2018 | 1272 | 0.160 |
Why?
|
| Endocardium | 6 | 2012 | 16 | 0.160 |
Why?
|
| Anniversaries and Special Events | 1 | 2019 | 3 | 0.150 |
Why?
|
| Membrane Potentials | 12 | 2001 | 64 | 0.150 |
Why?
|
| Ventricular Dysfunction | 1 | 1998 | 7 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 64 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2017 | 611 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 146 | 0.140 |
Why?
|
| Sotalol | 3 | 2007 | 9 | 0.140 |
Why?
|
| Cholinergic Agonists | 1 | 2017 | 6 | 0.140 |
Why?
|
| Anisotropy | 1 | 2017 | 28 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 68 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 34 | 0.130 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2017 | 62 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 524 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2012 | 391 | 0.130 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2016 | 3 | 0.130 |
Why?
|
| Botulinum Toxins | 1 | 2016 | 10 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2019 | 1009 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2017 | 176 | 0.120 |
Why?
|
| Graves Disease | 1 | 2015 | 8 | 0.120 |
Why?
|
| Thyroxine | 1 | 2015 | 11 | 0.120 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Middle Aged | 17 | 2020 | 7310 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 373 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 11 | 0.110 |
Why?
|
| Injections, Intravenous | 7 | 2009 | 66 | 0.110 |
Why?
|
| Glycogen | 1 | 2015 | 23 | 0.110 |
Why?
|
| Epicardial Mapping | 2 | 2017 | 8 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2015 | 45 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2015 | 202 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 633 | 0.110 |
Why?
|
| Calcium | 4 | 2006 | 243 | 0.110 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 36 | 0.110 |
Why?
|
| Heart Injuries | 1 | 2013 | 8 | 0.110 |
Why?
|
| Cryosurgery | 1 | 2013 | 19 | 0.100 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2013 | 17 | 0.100 |
Why?
|
| Dog Diseases | 1 | 1993 | 30 | 0.100 |
Why?
|
| Catheterization | 4 | 2003 | 50 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 293 | 0.100 |
Why?
|
| Microcirculation | 1 | 1993 | 113 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 8 | 0.100 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 21 | 0.100 |
Why?
|
| Inflammation | 1 | 2017 | 642 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 510 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2017 | 631 | 0.090 |
Why?
|
| Chromogranin A | 1 | 2012 | 3 | 0.090 |
Why?
|
| Probability | 3 | 2010 | 78 | 0.090 |
Why?
|
| Syncope, Vasovagal | 1 | 2012 | 5 | 0.090 |
Why?
|
| Propanolamines | 3 | 2013 | 16 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 3 | 1997 | 18 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2012 | 152 | 0.090 |
Why?
|
| Ventricular Function | 10 | 2000 | 25 | 0.090 |
Why?
|
| Phenytoin | 10 | 1971 | 15 | 0.090 |
Why?
|
| Cholinergic Fibers | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adrenergic Fibers | 1 | 2011 | 8 | 0.090 |
Why?
|
| Neurotoxins | 1 | 2010 | 7 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 32 | 0.090 |
Why?
|
| Magnetics | 1 | 2010 | 14 | 0.090 |
Why?
|
| Ventricular Fibrillation | 12 | 1998 | 40 | 0.080 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1990 | 14 | 0.080 |
Why?
|
| Tachycardia, Paroxysmal | 3 | 2009 | 7 | 0.080 |
Why?
|
| Vena Cava, Inferior | 2 | 2000 | 16 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 55 | 0.080 |
Why?
|
| Myocardial Contraction | 9 | 1996 | 62 | 0.080 |
Why?
|
| Seasons | 1 | 1990 | 94 | 0.080 |
Why?
|
| Ligation | 11 | 2007 | 39 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2015 | 1455 | 0.080 |
Why?
|
| Acute Disease | 5 | 2009 | 155 | 0.080 |
Why?
|
| Calcium Signaling | 1 | 2009 | 72 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 137 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 77 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2008 | 25 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1989 | 69 | 0.070 |
Why?
|
| Neurons | 1 | 2010 | 291 | 0.070 |
Why?
|
| Atracurium | 1 | 2008 | 3 | 0.070 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2008 | 2 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2020 | 421 | 0.070 |
Why?
|
| Isoquinolines | 1 | 2008 | 15 | 0.070 |
Why?
|
| Sodium-Calcium Exchanger | 2 | 2006 | 21 | 0.070 |
Why?
|
| Stroke Volume | 2 | 2018 | 124 | 0.070 |
Why?
|
| Bradycardia | 5 | 1982 | 17 | 0.070 |
Why?
|
| Reference Values | 3 | 2004 | 199 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1026 | 0.070 |
Why?
|
| Aged | 12 | 2020 | 5525 | 0.070 |
Why?
|
| Pacemaker, Artificial | 18 | 1977 | 56 | 0.070 |
Why?
|
| Ganglia | 1 | 2006 | 9 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 216 | 0.060 |
Why?
|
| Caffeine | 1 | 2006 | 39 | 0.060 |
Why?
|
| Catecholamines | 1 | 2005 | 18 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2002 | 61 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2015 | 131 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 247 | 0.060 |
Why?
|
| Papillary Muscles | 4 | 1996 | 15 | 0.060 |
Why?
|
| Ischemia | 3 | 1975 | 83 | 0.060 |
Why?
|
| Risk Factors | 4 | 2016 | 2111 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2006 | 622 | 0.050 |
Why?
|
| Afferent Pathways | 1 | 2004 | 62 | 0.050 |
Why?
|
| Microscopy | 1 | 2004 | 38 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 145 | 0.050 |
Why?
|
| Radial Neuropathy | 1 | 2003 | 1 | 0.050 |
Why?
|
| Radial Nerve | 1 | 2003 | 2 | 0.050 |
Why?
|
| Motor Neuron Disease | 1 | 2003 | 3 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2003 | 12 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2018 | 554 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 257 | 0.050 |
Why?
|
| Verapamil | 2 | 1995 | 9 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 34 | 0.050 |
Why?
|
| Digitalis Glycosides | 4 | 1971 | 5 | 0.050 |
Why?
|
| Equipment Design | 2 | 2000 | 218 | 0.050 |
Why?
|
| Resuscitation | 1 | 1983 | 59 | 0.050 |
Why?
|
| Isotonic Solutions | 1 | 2002 | 7 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 208 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 95 | 0.050 |
Why?
|
| Potassium | 4 | 1974 | 42 | 0.050 |
Why?
|
| Ouabain | 6 | 1992 | 8 | 0.050 |
Why?
|
| Purkinje Cells | 2 | 1979 | 7 | 0.040 |
Why?
|
| Tricuspid Valve | 2 | 1999 | 31 | 0.040 |
Why?
|
| Neural Conduction | 4 | 1976 | 26 | 0.040 |
Why?
|
| Procainamide | 6 | 1983 | 9 | 0.040 |
Why?
|
| Muscle Contraction | 3 | 2003 | 171 | 0.040 |
Why?
|
| Ion Channels | 1 | 1980 | 28 | 0.040 |
Why?
|
| Hemodynamics | 5 | 1996 | 221 | 0.040 |
Why?
|
| Diastole | 2 | 2018 | 22 | 0.040 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2000 | 1 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2008 | 782 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2000 | 20 | 0.040 |
Why?
|
| Ear, External | 1 | 2020 | 13 | 0.040 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 13 | 0.040 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 182 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 328 | 0.040 |
Why?
|
| Electronics, Medical | 1 | 1979 | 3 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2018 | 12 | 0.040 |
Why?
|
| Rats, Inbred Dahl | 1 | 2018 | 16 | 0.040 |
Why?
|
| Arrhythmia, Sinus | 2 | 1978 | 4 | 0.040 |
Why?
|
| Sinus of Valsalva | 1 | 1998 | 13 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2009 | 57 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 137 | 0.040 |
Why?
|
| Fluoroscopy | 2 | 1999 | 36 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 122 | 0.040 |
Why?
|
| Protein Binding | 2 | 2017 | 664 | 0.040 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2017 | 4 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2013 | 150 | 0.030 |
Why?
|
| Nadolol | 2 | 1988 | 3 | 0.030 |
Why?
|
| Chlorides | 2 | 1990 | 13 | 0.030 |
Why?
|
| Hypoxia | 1 | 1978 | 90 | 0.030 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 14 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 79 | 0.030 |
Why?
|
| Disopyramide | 3 | 2011 | 10 | 0.030 |
Why?
|
| Methods | 9 | 1986 | 27 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 1997 | 252 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 354 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2015 | 4 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 2 | 1987 | 18 | 0.030 |
Why?
|
| Coronary Sinus | 1 | 2015 | 4 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1993 | 56 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 194 | 0.030 |
Why?
|
| Radio Waves | 1 | 1995 | 21 | 0.030 |
Why?
|
| Adult | 8 | 2017 | 7922 | 0.030 |
Why?
|
| Antigens | 1 | 2015 | 68 | 0.030 |
Why?
|
| Quinidine | 2 | 2011 | 5 | 0.030 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 20 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 325 | 0.030 |
Why?
|
| Anesthesia, General | 2 | 1993 | 30 | 0.030 |
Why?
|
| Oklahoma | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 448 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 218 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 480 | 0.030 |
Why?
|
| Mice | 3 | 2017 | 4735 | 0.030 |
Why?
|
| Hungary | 1 | 1994 | 5 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1994 | 9 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1994 | 7 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 92 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 247 | 0.030 |
Why?
|
| Electron Transport | 1 | 1994 | 31 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 1994 | 25 | 0.030 |
Why?
|
| Pre-Excitation Syndromes | 1 | 1994 | 4 | 0.030 |
Why?
|
| Fibrosis | 1 | 2015 | 134 | 0.030 |
Why?
|
| Tetrodotoxin | 3 | 2005 | 12 | 0.030 |
Why?
|
| Magnesium Compounds | 1 | 1993 | 2 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1993 | 1 | 0.030 |
Why?
|
| Reperfusion | 1 | 1993 | 7 | 0.030 |
Why?
|
| Spin Labels | 1 | 1993 | 19 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1993 | 35 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 1993 | 26 | 0.030 |
Why?
|
| Brain | 1 | 2019 | 753 | 0.030 |
Why?
|
| Peroxidase | 1 | 1993 | 39 | 0.030 |
Why?
|
| Magnesium | 1 | 1993 | 42 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 1993 | 41 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1993 | 35 | 0.030 |
Why?
|
| Free Radicals | 1 | 1993 | 39 | 0.030 |
Why?
|
| Leukocytes | 1 | 1993 | 72 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 1993 | 53 | 0.030 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1993 | 10 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 475 | 0.020 |
Why?
|
| Adrenergic Neurons | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cholinergic Neurons | 1 | 2012 | 5 | 0.020 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1992 | 3 | 0.020 |
Why?
|
| Pyridines | 1 | 1973 | 108 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1992 | 10 | 0.020 |
Why?
|
| Sparteine | 1 | 1992 | 1 | 0.020 |
Why?
|
| Cardanolides | 2 | 1971 | 2 | 0.020 |
Why?
|
| Cerebral Ventriculography | 2 | 1971 | 3 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cell Polarity | 1 | 1991 | 22 | 0.020 |
Why?
|
| Acrylamides | 1 | 2010 | 5 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1971 | 104 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1996 | 73 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2010 | 43 | 0.020 |
Why?
|
| Lethal Dose 50 | 2 | 2000 | 14 | 0.020 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 1990 | 2 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2009 | 9 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 151 | 0.020 |
Why?
|
| Rats | 3 | 2003 | 1587 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2010 | 122 | 0.020 |
Why?
|
| Propafenone | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2009 | 6 | 0.020 |
Why?
|
| Electrodes | 5 | 2003 | 72 | 0.020 |
Why?
|
| Body Weight | 2 | 2000 | 250 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2009 | 17 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 1989 | 4 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 236 | 0.020 |
Why?
|
| Cesium | 2 | 1990 | 2 | 0.020 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 7 | 0.020 |
Why?
|
| Strophanthidin | 1 | 1968 | 1 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2008 | 31 | 0.020 |
Why?
|
| Perfusion | 2 | 1998 | 43 | 0.020 |
Why?
|
| Selenium | 1 | 1987 | 17 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 3165 | 0.020 |
Why?
|
| Ethanol | 1 | 1987 | 124 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2804 | 0.020 |
Why?
|
| Carbachol | 1 | 2006 | 18 | 0.020 |
Why?
|
| Ryanodine | 1 | 2005 | 3 | 0.010 |
Why?
|
| Atenolol | 1 | 2005 | 10 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 79 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 36 | 0.010 |
Why?
|
| Nitriles | 1 | 2003 | 33 | 0.010 |
Why?
|
| Hand Strength | 1 | 2003 | 38 | 0.010 |
Why?
|
| Heart Septum | 3 | 1998 | 16 | 0.010 |
Why?
|
| Arteries | 2 | 1993 | 66 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2003 | 54 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1994 | 273 | 0.010 |
Why?
|
| Evoked Potentials | 2 | 1973 | 49 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1983 | 44 | 0.010 |
Why?
|
| Molecular Conformation | 2 | 1996 | 67 | 0.010 |
Why?
|
| Atrial Premature Complexes | 1 | 2001 | 2 | 0.010 |
Why?
|
| Monensin | 1 | 1981 | 4 | 0.010 |
Why?
|
| Furans | 1 | 1981 | 5 | 0.010 |
Why?
|
| Drinking Behavior | 1 | 2000 | 6 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1980 | 40 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1978 | 43 | 0.010 |
Why?
|
| Research | 3 | 1965 | 93 | 0.010 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2000 | 2 | 0.010 |
Why?
|
| KATP Channels | 1 | 2000 | 2 | 0.010 |
Why?
|
| 4-Aminopyridine | 1 | 2000 | 3 | 0.010 |
Why?
|
| Drinking | 1 | 2000 | 8 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2000 | 15 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2000 | 38 | 0.010 |
Why?
|
| Parasympathectomy | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cervical Plexus | 1 | 1999 | 3 | 0.010 |
Why?
|
| Models, Molecular | 2 | 1996 | 452 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 1994 | 23 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2000 | 17 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1999 | 13 | 0.010 |
Why?
|
| Organ Size | 1 | 2000 | 88 | 0.010 |
Why?
|
| Veins | 1 | 2000 | 19 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1999 | 24 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 1999 | 38 | 0.010 |
Why?
|
| Eating | 1 | 2000 | 70 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2000 | 103 | 0.010 |
Why?
|
| Analog-Digital Conversion | 1 | 1979 | 2 | 0.010 |
Why?
|
| Carotid Sinus | 2 | 1969 | 2 | 0.010 |
Why?
|
| Filtration | 1 | 1979 | 8 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2000 | 172 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1998 | 19 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 232 | 0.010 |
Why?
|
| Necrosis | 1 | 1998 | 85 | 0.010 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1997 | 7 | 0.010 |
Why?
|
| Calcium Channel Agonists | 1 | 1997 | 7 | 0.010 |
Why?
|
| Nifedipine | 1 | 1997 | 12 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 456 | 0.010 |
Why?
|
| Calcium Channels | 1 | 1997 | 34 | 0.010 |
Why?
|
| Sodium | 1 | 1997 | 50 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 41 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1978 | 94 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 899 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1996 | 122 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 2 | 1994 | 50 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1995 | 2 | 0.010 |
Why?
|
| X-Ray Diffraction | 2 | 1987 | 41 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1996 | 222 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1996 | 244 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1995 | 18 | 0.010 |
Why?
|
| Half-Life | 1 | 1995 | 34 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1975 | 11 | 0.010 |
Why?
|
| Biological Availability | 1 | 1995 | 44 | 0.010 |
Why?
|
| Differential Threshold | 1 | 1975 | 2 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1987 | 180 | 0.010 |
Why?
|
| Aorta | 1 | 1995 | 124 | 0.010 |
Why?
|
| Submitochondrial Particles | 1 | 1994 | 2 | 0.010 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 1994 | 8 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1994 | 11 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1994 | 29 | 0.010 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1994 | 40 | 0.010 |
Why?
|
| Torsades de Pointes | 1 | 1994 | 3 | 0.010 |
Why?
|
| Magnesium Sulfate | 1 | 1993 | 4 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 1993 | 7 | 0.010 |
Why?
|
| Cell Separation | 1 | 1993 | 55 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1993 | 44 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 1992 | 4 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1992 | 54 | 0.010 |
Why?
|
| Calcium Gluconate | 1 | 1992 | 1 | 0.010 |
Why?
|
| Oxygen | 1 | 1973 | 234 | 0.010 |
Why?
|
| Sodium Channels | 1 | 1992 | 8 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 63 | 0.010 |
Why?
|
| Diatrizoate | 1 | 1971 | 1 | 0.010 |
Why?
|
| Angiocardiography | 1 | 1971 | 7 | 0.010 |
Why?
|
| Amino Sugars | 1 | 1971 | 2 | 0.010 |
Why?
|
| Metabolism | 1 | 1971 | 9 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1971 | 32 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1994 | 485 | 0.010 |
Why?
|
| Kinetics | 1 | 1991 | 551 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1990 | 5 | 0.010 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1970 | 16 | 0.010 |
Why?
|
| Prognosis | 3 | 1979 | 807 | 0.000 |
Why?
|
| Iontophoresis | 1 | 1968 | 3 | 0.000 |
Why?
|
| Reflex | 1 | 1969 | 74 | 0.000 |
Why?
|
| Chemistry | 1 | 1987 | 10 | 0.000 |
Why?
|
| Chemistry, Physical | 1 | 1987 | 13 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 22 | 0.000 |
Why?
|
| Blood Circulation | 1 | 1966 | 13 | 0.000 |
Why?
|
| Technetium | 1 | 1986 | 43 | 0.000 |
Why?
|
| Microspheres | 1 | 1986 | 49 | 0.000 |
Why?
|
| Cats | 1 | 1966 | 51 | 0.000 |
Why?
|
| Collateral Circulation | 1 | 1984 | 12 | 0.000 |
Why?
|
| Stereoisomerism | 1 | 1984 | 45 | 0.000 |
Why?
|
| Crystallization | 1 | 1984 | 50 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1984 | 109 | 0.000 |
Why?
|
| Ebstein Anomaly | 1 | 1983 | 10 | 0.000 |
Why?
|
| Methylprednisolone | 1 | 1982 | 15 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1974 | 269 | 0.000 |
Why?
|
| Nerve Crush | 1 | 1978 | 3 | 0.000 |
Why?
|
| Periodicity | 1 | 1977 | 17 | 0.000 |
Why?
|
| Practolol | 1 | 1976 | 5 | 0.000 |
Why?
|
| Synaptic Transmission | 1 | 1976 | 51 | 0.000 |
Why?
|
| Time | 1 | 1975 | 16 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1975 | 37 | 0.000 |
Why?
|
| Adams-Stokes Syndrome | 1 | 1974 | 1 | 0.000 |
Why?
|
| Isoproterenol | 1 | 1974 | 23 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1975 | 54 | 0.000 |
Why?
|
| Heart Arrest, Induced | 1 | 1974 | 2 | 0.000 |
Why?
|
| Syndrome | 1 | 1974 | 79 | 0.000 |
Why?
|
| Aortography | 1 | 1971 | 6 | 0.000 |
Why?
|
| Sodium Hydroxide | 1 | 1971 | 9 | 0.000 |
Why?
|
| Buffers | 1 | 1971 | 25 | 0.000 |
Why?
|
| Cerebral Angiography | 1 | 1971 | 38 | 0.000 |
Why?
|
| Benzoates | 1 | 1971 | 30 | 0.000 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 1970 | 13 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1970 | 378 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1968 | 17 | 0.000 |
Why?
|
| Digitalis | 1 | 1967 | 1 | 0.000 |
Why?
|
| Plants, Toxic | 1 | 1967 | 1 | 0.000 |
Why?
|
| Plants, Medicinal | 1 | 1967 | 18 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1968 | 58 | 0.000 |
Why?
|
| Drug Antagonism | 1 | 1967 | 2 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1968 | 259 | 0.000 |
Why?
|
| Child | 1 | 1970 | 2271 | 0.000 |
Why?
|